

IMPENDING RETIREMENT OF DIRECTOR – JAMES JOUGHIN

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the 'Company'), an agtech development company enabling the next generation of novel insecticides, announces that Mr. James Joughin has advised, that due to increasing commitments associated with his Chairmanship and NED roles on other ASX companies, he will retire from the Board of the Company effective as from 30 June 2023.

James has been a very important member of the Company's Board and we thank him for his wise inputs. Mr. Andrew Guthrie will assume Chairmanship of the Company's Audit and Risk committee from 1 July 2023.

Approved for release by the Chairman of the Board of Directors.

- ENDS -

For further information, please contact:

IR/Media

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer

P: 03 9068 1062

E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary

P: 03 9068 1062

E: bgt.info@bio-gene.com.au

Adrian Mulcahy
Automic Group

P: 0438 630 422

E: adrian.mulcahy@automicgroup.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.